The Association Between BRCA1 Gene Polymorphism and Cancer Risk: a Meta-analysis

Overview

Journal Oncotarget

Specialty Oncology

Date 2018 Mar 2

PMID 29492227

Citations 17

Authors

Gui-Ping Xu

Qing Zhao

Ding Wang

Wen-Yue Xie

Li-Jun Zhang

Hua Zhou

Shi-Zhi Chen

Li-Fang Wu

Affiliations

Soon will be listed here.

Abstract

Many studies have reported that BRCA1 polymorphisms are associated with cancer risk, but the results remain controversial. The purpose of this meta-analysis is to evaluate the relationship between BRCA1 polymorphisms (rs799917, rs1799950, rs1799966, or rs16941) and cancer risk. Relevant studies were identified via a systematic search of the PubMed, Embase, and Web of Science databases up to July 31, 2017. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to examine the strength of the associations. Thirty-five studies published in 19 publications involving 28,094 cases and 50,657 controls were included in this meta-analysis. There was no obvious association between rs799917, rs1799966, or rs16941 polymorphisms and overall cancer risk in any genetic models. However, subgroup analyses revealed that the rs799917 polymorphism could decrease the risk of cervical cancer, esophageal squamous cell carcinoma (ESCC), gastric cancer, and non-Hodgkin lymphoma (NHL) among Asian populations in one or more genetic models and that rs16941 could increase overall cancer risk among Caucasian populations in the homozygote and recessive models. Our meta-analysis also indicated that rs1799950 could decrease the breast cancer (BC) risk among Caucasian populations in the homozygote and recessive models. In summary, our results suggest that BRCA1 polymorphisms may play an important role in the etiology of cancer. However, due to the limited number of studies, these findings should be confirmed by new studies with larger sample sizes that address various types of cancer.

Citing Articles

Regional Hereditary Cancer Program in Chile: A scalable model of genetic counseling and molecular diagnosis to improve clinical outcomes for patients with hereditary cancer across Latin America.

Landeros N, Vargas-Roig L, Denita S, Mampel A, Hasbun R, Araya H Biol Res. 2024; 57(1):99.

PMID: 39710803 PMC: 11664851. DOI: 10.1186/s40659-024-00579-x.

Comprehensive breast cancer risk analysis with whole exome sequencing and the prevalence of and mutations and oncogenic HPV.

Bumrungthai S, Duangjit S, Passorn S, Pongpakdeesakul S, Butsri S, Janyakhantikul S Biomed Rep. 2024; 21(4):144.

PMID: 39170756 PMC: 11337157. DOI: 10.3892/br.2024.1832.

Frequencies of Diagnostically Significant Polymorphisms of Hereditary Breast Cancer Forms in BRCA1 and BRCA2 Genes in the Kazakh Population.

Svyatova G, Berezina G, Urazbayeva G, Murtazaliyeva A Asian Pac J Cancer Prev. 2023; 24(11):3899-3907.

PMID: 38019249 PMC: 10772761. DOI: 10.31557/APJCP.2023.24.11.3899.

Significant association of BRCA1 (rs1799950), BRCA2 (rs144848) and TP53 (rs1042522) polymorphism with breast cancer risk in Pashtun population of Khyber Pakhtunkhwa, Pakistan.

Khan Y, Khan N, Ali I, Khan S, Khan A, Iqbal A Mol Biol Rep. 2023; 50(7):6087-6096.

PMID: 37300745 DOI: 10.1007/s11033-023-08463-9.

VUS: A functional analysis to differentiate pathogenic from benign variants identified in clinical diagnostic panels for breast cancer.

Lourenco R, Lanca M, Gil O, Cardoso J, Lourenco T, Pereira-Leal J Mol Med Rep. 2023; 28(1).

PMID: 37232349 PMC: 10280555. DOI: 10.3892/mmr.2023.13023.

References

Thompson D, Easton D . Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst. 2002; 94(18):1358-65. DOI: 10.1093/jnci/94.18.1358. View

Huo X, Lu C, Huang X, Hu Z, Jin G, Ma H . Polymorphisms in BRCA1, BRCA1-interacting genes and susceptibility of breast cancer in Chinese women. J Cancer Res Clin Oncol. 2009; 135(11):1569-75. DOI: 10.1007/s00432-009-0604-6. View

Maia A, Spiteri I, Lee A, OReilly M, Jones L, Caldas C . Extent of differential allelic expression of candidate breast cancer genes is similar in blood and breast. Breast Cancer Res. 2009; 11(6):R88. PMC: 2815552. DOI: 10.1186/bcr2458. View

Higgins J, Thompson S . Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-58. DOI: 10.1002/sim.1186. View

Venkitaraman A . Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell. 2002; 108(2):171-82. DOI: 10.1016/s0092-8674(02)00615-3. View

Wang Z, Xu Y, Tang J, Ma H, Qin J, Lu C . A polymorphism in Werner syndrome gene is associated with breast cancer susceptibility in Chinese women. Breast Cancer Res Treat. 2009; 118(1):169-75. DOI: 10.1007/s10549-009-0327-z. View

Tian X, Dai S, Sun J, Jiang S, Jiang Y . Association between TP53 Arg72Pro polymorphism and leukemia risk: a meta-analysis of 14 case-control studies. Sci Rep. 2016; 6:24097. PMC: 4823650. DOI: 10.1038/srep24097. View

Deng C, Brodie S . Roles of BRCA1 and its interacting proteins. Bioessays. 2000; 22(8):728-37. DOI: 10.1002/1521-1878(200008)22:8<728::AID-BIES6>3.0.CO;2-B. View

Li W, Hu N, Hyland P, Gao Y, Wang Z, Yu K . Genetic variants in DNA repair pathway genes and risk of esophageal squamous cell carcinoma and gastric adenocarcinoma in a Chinese population. Carcinogenesis. 2013; 34(7):1536-42. PMC: 3697889. DOI: 10.1093/carcin/bgt094. View

10.

Zuhlke K, Madeoy J, Beebe-Dimmer J, White K, Griffin A, Lange E . Truncating BRCA1 mutations are uncommon in a cohort of hereditary prostate cancer families with evidence of linkage to 17q markers. Clin Cancer Res. 2004; 10(18 Pt 1):5975-80. DOI: 10.1158/1078-0432.CCR-04-0554. View

11.

Zhang X, Wei J, Zhou L, Zhou C, Shi J, Yuan Q . A functional BRCA1 coding sequence genetic variant contributes to risk of esophageal squamous cell carcinoma. Carcinogenesis. 2013; 34(10):2309-13. DOI: 10.1093/carcin/bgt213. View

12.

Begg C, Mazumdar M . Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50(4):1088-101. View

13.

Dunning A, Chiano M, Smith N, Dearden J, Gore M, Oakes S . Common BRCA1 variants and susceptibility to breast and ovarian cancer in the general population. Hum Mol Genet. 1997; 6(2):285-9. DOI: 10.1093/hmg/6.2.285. View

14.

Hasan T, Shafi G, Syed N, Alsaif M, Alsaif A, Alshatwi A . Lack of association of BRCA1 and BRCA2 variants with breast cancer in an ethnic population of Saudi Arabia, an emerging high-risk area. Asian Pac J Cancer Prev. 2013; 14(10):5671-4. DOI: 10.7314/apjcp.2013.14.10.5671. View

15.

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

16.

Lichtenstein P, Holm N, Verkasalo P, Iliadou A, Kaprio J, Koskenvuo M . Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000; 343(2):78-85. DOI: 10.1056/NEJM200007133430201. View

17.

Bougie O, Weberpals J . Clinical Considerations of BRCA1- and BRCA2-Mutation Carriers: A Review. Int J Surg Oncol. 2012; 2011:374012. PMC: 3263675. DOI: 10.1155/2011/374012. View

18.

Soucek P, Borovanova T, Pohlreich P, Kleibl Z, Novotny J . Role of single nucleotide polymorphisms and haplotypes in BRCA1 in breast cancer: Czech case-control study. Breast Cancer Res Treat. 2006; 103(2):219-24. DOI: 10.1007/s10549-006-9367-9. View

19.

Koberle B, Koch B, Fischer B, Hartwig A . Single nucleotide polymorphisms in DNA repair genes and putative cancer risk. Arch Toxicol. 2016; 90(10):2369-88. DOI: 10.1007/s00204-016-1771-2. View

20.

Dombernowsky S, Weischer M, Freiberg J, Bojesen S, Tybjaerg-Hansen A, Nordestgaard B . Missense polymorphisms in BRCA1 and BRCA2 and risk of breast and ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2009; 18(8):2339-42. DOI: 10.1158/1055-9965.EPI-09-0447. View